Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 9—September 2003


DNA Vaccine for West Nile Virus Infection in Fish Crows (Corvus ossifragus)

Michael J. Turell*Comments to Author , Michel L. Bunning†‡1, George V. Ludwig*, Brian Ortman†, Jeff Chang‡, Tully Speaker§, Andrew Spielman¶, Robert McLean#, Nicholas Komar‡, Robert Gates‡, Tracey McNamara**, Terry Creekmore††, Linda Farley‡‡, and Carl J. Mitchell‡
Author affiliations: *U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; †U.S. Air Force, Fort Detrick, Maryland, USA; ‡Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; §Temple University, Philadelphia, Pennsylvania, USA; ¶Harvard School of Public Health and the Center for International Development at Harvard University, Boston, Massachusetts, USA; #U.S. Department of Agriculture, Fort Collins, Colorado, USA; **Wildlife Conservation Society, Bronx, New York, USA; ††Wyoming Department of Health, Laramie, Wyoming, USA; ‡‡American Bird Conservancy, Washington, D.C., USA; 1Drs. Turell and Bunning are co-lead authors of this article.

Main Article

Table 2

Viremia levels in fish crows that survived or died after challenge with virulent West Nile virus

Treatmenta Survived (peak)
No. Viremiab No. Peak viremiab
2.9 (0.4)
3.6 (0.7)
6.9 (1.0)
Placebo 5 3.8 (0.4) 5 4.8 (0.4)

          aIM, intramuscularly. Crows were inoculated IM with 0.5 mg of the DNA vaccine. Oral, crows were given 0.5 mg of the DNA vaccine orally. Placebo, crows were inoculated IM with 0.5 mg of nonspecific DNA and given 0.5 mg of nonspecific DNA orally.
          bLogarithm mean peak viremia in crows bled every third day after challenge (S.E.). A value
          of 1.7 was assigned to birds from which no virus was detected for calculation of mean and S.E.

Main Article